- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00115921
Evaluation of Home-Based Management of Fever in Urban Ugandan Children
Study Overview
Status
Intervention / Treatment
Detailed Description
Population: Representative sample of Ugandan children aged 1 to 5 years from 400 households (approximately 540 children).
Clinical Site: The study will be conducted in the Mulago III parish community of Kampala, Uganda.
Study Duration: 13 months
Study Intervention: *Pilot period: After enrollment, households will participate in a one month pilot period to test the household pictorial diaries. At the end of the pilot period, households will be randomized to participation in the home-based management of fever (HBMF) arm or standard care arm for the remainder of the study (12 months). *HBMF arm: Households randomized to the HBMF group will be provided with pre-packaged coartemether to keep at home. Primary caregivers will be instructed to treat children participating in the study empirically with coartemether at home when the child develops fever. Study personnel will distribute drugs and educate the caregivers about administration of drugs, recognition of danger signs of fever/malaria, and when to seek additional care. *Standard care: Households randomized to the standard care arm will be asked to continue their current behaviour and to manage fever in their children as they would normally.
Measurements: Household diaries and monthly visits. Primary caregivers will be asked to keep a diary regarding the health of study participants for the duration of the study (13 months). Information on illnesses, treatments given, visits to health care facilities, and health care expenditures will be collected. Study personnel will visit the households monthly to collect completed diaries. At each visit, questionnaires will be administered to gather additional data on the health of the participants and treatment seeking behaviour.
Clinical and laboratory evaluations: Temperature, height, weight, mid-upper arm circumference, spleen size, haemoglobin, and thick blood smear will be assessed at enrollment, and at the beginning and end of the intervention period.
Study Objectives: 1. To measure the impact of home-based management of fever with coartemether on malaria-related morbidity compared to the current standard of care in the community.
2. To measure the impact of home-based management of fever with coartemether on economic measures compared to the current standard of care in the community.
Primary outcome: Treatment incidence density (treatments per time at risk) for each treatment arm
Secondary clinical outcomes: 1) mean days of fever; 2) incidence of febrile episodes; 3) mean haemoglobin at study end; 4) change in mean haemoglobin; 5) prevalence of splenomegaly; 6) prevalence of parasitaemia; 7) incidence of visits to health care facilities, and hospitalizations; 8) mortality rate; 9) anthropometric measurements; 10) proportion of "appropriate" treatments; 11) proportion of delayed treatments; 12) treatment incidence density of treatments given at >50% and at full dose
Economic outcomes: 1) household cost/febrile episode; 2) household costs for treatment of febrile episode/month; 3) provider cost/child for delivery of HBMF; 4) estimated provider facility cost/patient for uncomplicated fever, and for severe disease; 5) total net cost/child/year; 6) net cost/additional child appropriately treated; 7) net cost/day of fever averted
Study Type
Enrollment
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 1 - 5 years
- Agreement of parents or guardians to provide informed consent
- Live in Mulago III Parish
Exclusion Criteria:
- History of any known serious chronic disease requiring frequent medical care (e.g. AIDS, sickle cell disease, malignancy)
- Intention to move from Kampala during the 13 month follow-up period
- History of serious side effects to study medications
- Weight < 10 kg
- Severe malnutrition defined as a weight-for-height or height-for-age Z-score < - 3
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
The primary outcome measurement will be treatment incidence density (antimalarial treatments received per time at risk) for each study arm.
|
Secondary Outcome Measures
Outcome Measure |
---|
Mortality rate
|
Mean days of fever per participant
|
Incidence of febrile episodes
|
Mean haemoglobin at study end
|
Change in mean haemoglobin between the start and end of the intervention
|
Incidence of visits to health care facilities (drug shops, clinics, pharmacies, hospitals) and hospitalizations per participant
|
Economic outcomes
|
Collaborators and Investigators
Investigators
- Principal Investigator: Sarah G Staedke, MD, University of California, San Francisco
- Principal Investigator: Christopher JM Whitty, FRCP, London School of Hygiene and Tropical Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ITCRVG40
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
-
Hospital Universitario Dr. Jose E. GonzalezCompletedPernicious Anemia | Megaloblastic Anemia NosMexico
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
Abdelwahed, Mai Mahmoud Mohamed, M.D.UnknownAnemia During PregnancyEgypt
-
University of California, DavisInstituto Mexicano del Seguro Social; Thrasher Research Fund; Mexican National... and other collaboratorsCompleted
-
Incyte CorporationActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
-
Peking Union Medical College HospitalRecruiting
-
Alexion PharmaceuticalsWithdrawnWarm Autoimmune Hemolytic AnemiaUnited States
Clinical Trials on Provision of antimalarial treatment at home
-
VA Office of Research and DevelopmentCompleted
-
Carlos III Health InstituteSpanish Society of Pneumology and Thoracic SurgeryUnknown
-
Azienda Ospedaliera San Giovanni BattistaCompletedCOPD Exacerbation
-
Johns Hopkins UniversityVirginia Polytechnic Institute and State University; Johns Hopkins Discovery...Completed
-
Johns Hopkins UniversityNational Institute of Neurological Disorders and Stroke (NINDS); Virginia Polytechnic...CompletedCerebellar Ataxia | Spinocerebellar Ataxias | Cerebellar DegenerationUnited States
-
Accumbo ABUniversity Hospital, LinkoepingCompleted
-
VISN 17 Center of ExcellenceUnited States Department of Defense; University of Texas at AustinEnrolling by invitation
-
Defactum, Central Denmark RegionViborg Regional Hospital; Interdisciplinary Centre for Organizational Architecture... and other collaboratorsRecruiting
-
Universidad de ZaragozaCompletedRehabilitation | Cervical VertigoSpain
-
University Hospital, Gentofte, CopenhagenMinistry of the Interior and Health, DenmarkCompleted